AZYO Aziyo Biologics

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET).

LD Micro Main Event XIX Conference

Presentation Date: Tuesday, October 21, 2025

Presentation Time: 1:00 p.m. PT (4:00 p.m. ET)

Webcast: 

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro representative or email .

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit .

Investors:

Matt Steinberg

FINN Partners

This press release was published by a CLEAR® Verified individual.



EN
14/10/2025

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday...

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). LD Micro Main Event XIX ConferencePresentation Date: Tuesday, October 21, 2025Presentation Time: 1:00 p.m. PT (4:00 p.m. ET)Webcast:  Elutia management will also...

October 14, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board o...

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company’s Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In conjunction with Mr. Neels’ appointment, W. Matthew Zuga and Maybelle Jordan have bo...

October 10, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scient...

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the closing of the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporatio...

October 1, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces Newly Published Clinical Data Demonstrating that Biol...

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation - Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management - GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of clinical and preclinical data supporting the clinical utility of a biologic envelope that secures cardiac implantab...

September 16, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Cor...

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million - Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET - GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definit...

September 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch